Drugs / RO7771950
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07413939 | May 2026 → May 2029 expected | HER2 positive breast carcinoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7771950 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07413939 ↗ |
| Route | Oral | “Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID).” NCT07413939 ↗ |